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Langerhans cell histiocytosis (LCH) is an uncom-
mon proliferative disorder of the Langerhans cells 
and antigen-presenting cells of the dendritic cell 
line.  The usual clinical presentation reveals patho-
logical masses or granulomatosis with destruction 
of surrounding tissues9).  The lesions are dominated 
by Langerhans cells, which are bone marrow derived 
cells of the dendritic cell line with antigen present-
ing and processing properties.  They are involved in 
a variety of immune responses and are found in the 
normal brain parenchyma and pituitary gland10,11). 
The most common presentation of LCH is that of a 
solitary skeletal lesion, usually of the calvarium, 
and it predominantly affects children, adolescents, 
or young adults.  Here we present two cases of soli-
tary cranial LCH, both of which presented with 
symptoms after trauma.  The lesions were examined 
pathologically and compared with the abnormal find-
ings on MRI.
Case 1
A 4-year-old boy came with a complaint of left 
temporal region pain and fever for one month.  He 
had history of a fall from a 50-cm height with bruis-
ing on the left temple without loss of consciousness 
approximately one month prior to his complaint.  On 
examination, he had left eye swelling without red-
ness and slight exophthalmos with fever.  A CT scan 
showed bony erosion accompanied by soft tissue 
involvement in and around the left orbit (Fig. 1A). 
There was obvious osseous destruction involving 
parts of the sphenoid wing (Fig. 1B).  An MRI study 
showed a lesion centered in the left retro-orbital 
space, extending into the middle cranial fossa.  The 
intraorbital extension caused a mass effect upon the 
external rectus muscles, optic nerve, and globe. 
There was no intraconal extension.  On T1-weighted 
image, it was slightly hyperintense (Fig. 1C), hy-
pointense on T2-weighted image (Fig. 1D) and en-
hanced on gadolinium administration (Fig. 1E).  A 
skeletal survey and whole body bone scan confirmed 
that the lesion was limited to the left orbit, with no 
other bony involvement.  Gallium 67 scan of the head 
showed increased uptake corresponding to the left 
orbital bone lesion as seen on the CT (Fig. 1F).  The 
patient underwent surgery for biopsy of the lesion 
(Fig. 1G).  Histopathologically, clefted and lobulated 
large multineucleated histiocyte-like or Langerhans 
cells along with infiltration of lymphocytes, neutro-
phils and eosinophils were observed (Fig. 2A & 2B). 
Furthermore, the histiocyte-like cells were immuno-
histochemically positive for CD68 (Fig. 2C), CD1a 
(Fig. 2D) and S100 (Fig. 2F).  Immunostaining was 
also positive for vemintin (Fig. 2E).  MIB-1 index 
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Fig. 1. Neuroimaging of Case 1
A. Axial non-contrast computed tomography (CT) scan showing a hyperdense lesion in left orbit and sphenoid region.
B. A three-dimensional CT scan showing osteolytic lesion on left orbital and sphenoidal bone.
C.  Axial T1-weighted magnetic resonance image (MRI) demonstrating a slightly hyperintense mass around left 
lateral orbital wall and sphenoid bone.
D. Axial T2-weighted MRI reveals an hypointense mass in the left lateral orbit and sphenoid bone.
E. Axial T1-weighted contrast enhanced MRI showing heterogeneously enhancing lesion.
F. Gallium 67 scan of the head showed vague, increased uptake on the left orbital bone.
G. Intraoperative photograph showing site of biopsy of the lesion on supero-lateral wall of left orbit.
Fig. 2. Pathology of Case 1
A.  Hematoxylin and Eosin (H & E) staining (original: × 400) showing large number of eosinophils while lower left 
panel shows clefted and lobulated Langerhans cells.
B.  Hematoxylin and Eosin (H & E) staining (original: × 400) showing giant multinucleated forms of Langerhans cells 
(arrow).
C. Immunohistochemistry showing positivity for macrophage marker CD 68 (original: × 400).
D. Immunohistochemistry showing positivity for histiocytic marker CD 1a (original: × 400).
E. mmunohistochemistry showing positivity for vimentin (original: × 400).
F.  Positive immunohistochemical staining for antibody to S-100 protein is seen as dark brown areas in both the 
nucleus and cytoplasm of the Langerhans cells.  Note ‘pac-man’ appearance (arrows) of the nucleus as a result of a 
prominent nuclear groove (original: × 400).  
G. MIB-1 staining of specimen (original: × 400).
H. Axial T1-weighted magnetic resonance image (MRI) demonstrating regression of lesion.
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demonstrated a right parietal extra-cranial mass, 
ovoid in appearance, with an adjacent skull defect 
involving the inner and outer tables.  The lesion 
was hyperintense on T1-weighted image (Fig. 3A) 
with heterogeneous intensity on T2-weighted image 
(Fig. 3B) and enhancement on gadolinium adminis-
tration (Fig. 3C).  Of concern was adjacent meninge-
al enhancement and there was slight signal change 
within the adjacent brain parenchyma.  The patient 
underwent surgery and total removal of the mass 
was achieved with repair of the skull using titani-
um plate.  Post-operative Gallium scintigraphy of 
whole body showed no other lesion.  Histopatholog-
ically, Langerhans cell was seen in the form of a 
giant multineucleated cell (Fig. 3D).  Staining was 
also positive for CD68 (Fig. 3E), CD1a (Fig. 3F), 
vemintin (Fig. 3G) and S100 (Fig. 3H).  MIB-1 in-
dex was 14%.  Follow-up MRI was performed 5 and 
7 years after operation and showed no reoccurrence.
was 19%.   Bone marrow biopsy showed no invasion 
of Langerhans cell.  Postoperatively prednisolone 
was administered at 40 mg/m2 per day for one month 
which improved his symptoms, thus the dose was 
reduced to 1.7 mg per kg body weight per oral.  The 
patient was followed up for 5 months after biopsy; 
MRI showed marked regression of the lesion; after 
which, he continued with a low dose oral steroid 
(Fig. 2H).
Case 2
An 8-year-old boy presented with a complaint of 
a gradually increasing round bump on his right 
parietal area.  He had been hit in the same area 2 
months earlier while practicing Judo and was oper-
ated to remove a subcutaneous hematoma.  On ex-
amination, occipital lymph nodes were swollen to 
about 1 cm in diameter.  On skull X-ray, 3.0 × 2.5 
cm bony erosion was detected.  MRI (Figs.  3A-C) 
Fig. 3. Neuroimaging and pathology of Case 2
A. Sagittal T1-weighted magnetic resonance image (MRI) demonstrating a hyperintense lesion in right parietal skull bone.
B. Axial T1-weighted MRI demonstrating a slightly hyperintense mass in right parietal region.
C. Axial T1-weighted contrast enhanced MRI showing enhancing lesion with slight brain parenchymal enhancement.
D. Hematoxylin and Eosin (H & E) staining (original: × 400) showing giant multinucleated forms of Langerhans cells.
E. Immunohistochemistry showing positivity for macrophage marker CD 68 (original: × 400).
F. Immunohistochemistry showing positivity for histiocytic marker CD 1a (original: × 400).
G. Immunohistochemistry showing positivity for vimentin (original: × 400).
H.  Positive immunohistochemical staining for antibody to S-100 protein similar to first case.  Note ‘pac-man’ 
appearance (arrows) of the nucleus (original: × 400).
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is the most common symptom and dislocation of the 
globe has also been reported26).  Despite its rarity, 
reported to be as low as 0.01% of orbital biopsies in 
children23), even if the CT appearance may look ag-
gressive, the possibility of Langerhans cell histiocy-
tosis must be kept in mind when examining a young 
child with orbital and periorbital lesion.  Central 
nervous system sequela is concerned in orbital LCH, 
but there is little evidence that orbital unifocal cases 
increase that risk8).  The differential diagnoses of 
the orbital LCH include metastatic neuroblastoma 
as well as mesenchymal osteogenic sarcoma.  All 
these pathologies can present as a rapidly pro-
gressing facial and orbital swelling.  The initial 
differential diagnosis of the first case was a focal 
infection following trauma and neoplastic lesion. 
A biopsy was done and yielded the final result of 
LCH.
Pathologically, LCH presents as typical granu-
lomas or as xanthogranulomas, characteristics of 
chronic inflammation18), i.e typical granulomas con-
sist of an accumulation of CD1a-positive (+) Langer-
hans cells, indeterminate and interdigitating cells, 
macrophages and T-lymphocytes.  Typically, the his-
tiocytic cells have folded nuclei.  The Langerhans 
cell infiltrate is accompanied by a varying amount 
of osteoclast-like giant cells and eosinophils.  The 
combination of immunopositivity for the neuronal 
marker S100 and CD1a, which is specific for Lang-
erhans cells (and thymocytes) and is not expressed 
by macrophages, helps to confirm the diagnosis13).
Various ways to treat the unifocal LCH have been 
described in the literature.  Some LCH show spon-
taneous regression; therefore, treatment may not be 
required12).  Partial resection or complete excisional 
biopsy of the lesion helps in definite diagnosis.  Bi-
opsy followed by low-dose radiation to the lesion 
usually with 6−10 Gy has a local control rate of 
approximately 80%11).  Unifocal LCH can also be 
treated with peroral or intralesional corticoste-
roids4).  Further options, especially for multifocal 
or aggressive LCH, include first line chemotherapy 
with a combination of prednisone/ vinblastine or 
second line agents with a 24 weeks course consist-
ing of prednisolone, vincristine and cytarabin2).
In conclusion, we reviewed two cases of LCH lim-
ited to one part of the skull coincident with the site 
of a preceding injury.  Although there are various 
treatment options for unifocal LCH, prednisone 
alone appears justified and may avoid overtreat-
ment with subsequent complications from radiation 
or chemotherapy.  However, long term follow-up 
with serial imaging is recommended.
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DISCUSSION
Langerhans cell histiocytosis (LCH) is a rare 
disease that is found mostly in children, with an 
estimated incidence between 0.2 and 2.0 cases per 
100,000 children under 15 years of age and a peak 
incidence at ages 2−47).  This disease has a prepon-
derance in males, sometimes as high as 60−70%17). 
The incidence appears to be higher in whites of 
northern European descent than in blacks14).  The 
most common site involved is the skull and accounts 
for more than 50% of cases.  The most common pre-
sentation is a painful immobile mass in the calvari-
um9).  The frequency of diabetes insipidus, the 
hallmark of hypothalamic pituitary region (HPR) 
involvement, is 5−50%10), whereas the estimated 
incidence of neurodegenerative LCH is 1−3%10,25). 
CT scanning helps in confirming the presence of the 
bone lesion and soft-tissue involvement.  MR imag-
ing is more useful for precise delineation of the ex-
tent of the soft-tissue lesions and their relationship 
to adjacent structures.
The etiology of LCH remains unknown, and it is 
still uncertain whether LCH is a neoplastic disor-
der, suggested by the monoclonality in lesions, or a 
reactive disorder resulting from a dysregulation of 
the immune system19,25).  Both of our cases had pre-
ceding trauma, and there is a report in which trau-
ma was the first presentation of LCH in orbit6). 
Acute injury triggered MyD88 dependent inflam-
matory responses16).  MyD88 plays an important 
role with extracellular signal-regulated kinase in 
brain22).  Preceding trauma might be coincidental 
but it is plausible that trauma accelerates immune 
system activation of undiagnosed LCH.
A single skull lesion may be the only presenting 
symptom.  However, there may be an underlying 
multifocal disease that can be investigated by nu-
clear medicine techniques.  In our second case, 
scintigraphy of whole body showed no other lesion. 
Additional changes of bone may occur for as long 
as 4 years after initial diagnosis which determines 
the disease prognosis1).  The multiplicity of clinical 
forms of LCH is accompanied by a great variation 
in outcome.  The localized focal form of LCH has a 
more favorable prognosis than the multifocal dis-
seminated form, which involves organs as well as 
the skeletal system20).
Involvement of the orbit by LCH is uncommon and 
accounts for less than 1% of all orbital tumors21). 
In most cases, LCH in orbit is present as a symptom 
with multisystem disease and multifocal bone dis-
ease8).  The most frequent presenting signs are pro-
ptosis, periocular redness, pain, and upper eyelid 
edema15).  When the orbit is involved, it is usually the 
superolateral aspect3).  Orbital masses are usually 
extraconal and are thought to be of bone origin5). 
If clinical signs are present, a lytic lesion of the or-
bital wall is usually found, as in our case.  Proptosis 
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